Rhythm Pharmaceuticals (RYTM) Equity Average (2017 - 2025)
Historic Equity Average for Rhythm Pharmaceuticals (RYTM) over the last 9 years, with Q3 2025 value amounting to $68.5 million.
- Rhythm Pharmaceuticals' Equity Average rose 17079.59% to $68.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.5 million, marking a year-over-year increase of 17079.59%. This contributed to the annual value of $95.7 million for FY2024, which is 5588.05% down from last year.
- As of Q3 2025, Rhythm Pharmaceuticals' Equity Average stood at $68.5 million, which was up 17079.59% from $3.5 million recorded in Q2 2025.
- Rhythm Pharmaceuticals' Equity Average's 5-year high stood at $366.3 million during Q2 2021, with a 5-year trough of $3.5 million in Q2 2025.
- Over the past 5 years, Rhythm Pharmaceuticals' median Equity Average value was $201.0 million (recorded in 2023), while the average stood at $178.9 million.
- Within the past 5 years, the most significant YoY rise in Rhythm Pharmaceuticals' Equity Average was 17079.59% (2025), while the steepest drop was 9302.54% (2025).
- Rhythm Pharmaceuticals' Equity Average (Quarter) stood at $303.2 million in 2021, then fell by 10.05% to $272.7 million in 2022, then plummeted by 32.67% to $183.6 million in 2023, then tumbled by 91.03% to $16.5 million in 2024, then skyrocketed by 315.58% to $68.5 million in 2025.
- Its Equity Average was $68.5 million in Q3 2025, compared to $3.5 million in Q2 2025 and $20.3 million in Q1 2025.